OneSource Specialty Pharma Expands DDC Capacity to 950 Litres by 2026
NEWZA Editorial Team•
⚡ Key Financial Takeaways
OneSource is the sole CDMO with generic semaglutide approvals in all G7 countries.
DDC capacity at the Bangalore plant grew 3.5‑5× to 700‑950 litres in September 2026.
An additional 500‑750 litres of DDC capacity is slated for March 2027.
Five new biologics and biosimilars clients have been onboarded, with mammalian and microbial capacities set to double and sextuple respectively.
ICICI Securities maintains a BUY rating with a target price of INR 2,400.
💡 Why It Matters
OneSource’s capacity expansion directly addresses the growing global demand for generic semaglutide, a high‑margin product. By scaling its DDC and biologics operations, the company can capture a larger share of the market, enhance its competitive edge, and deliver stronger financial performance for investors.
Semaglutide Market Leadership OneSource Specialty Pharma has carved a niche as the only contract development and manufacturing organisation (CDMO) that holds generic semaglutide approvals across the G7 nations. Its existing customers have made significant inroads in India, Canada and Saudi Arabia, and the company is poised to extend its reach to Brazil, Turkey, Latin America and Southeast Asia in the coming months.
Capacity Expansion Milestones During a recent visit to its Bangalore drug‑device combination (DDC) plant, ICICI Securities noted a dramatic scale‑up. The facility’s output has been increased by roughly 3.5‑5 times, bringing the annual capacity to between 700 and 950 litres as of September 2026. To meet the projected demand for FY28, OneSource plans an additional 500‑750 litres of DDC capacity in March 2027.
Broadening Biologics Footprint Beyond semaglutide, the firm is diversifying into biologics and biosimilars. Five new client partnerships have been secured, and the company is expanding its mammalian production line by about twofold while boosting microbial capacity sixfold. These moves position OneSource to serve a wider array of therapeutic areas.
Investment Outlook ICICI Securities keeps a BUY recommendation on the stock, maintaining a target price of INR 2,400. The firm’s aggressive capacity build‑out and expanding client base underpin the positive outlook.
Key Takeaways - Only CDMO with generic semaglutide approvals in all G7 nations. - DDC capacity now 700‑950 litres; 500‑750 litres to add in March 2027. - Five new biologics clients; mammalian and microbial capacities to double and sextuple. - ICICI’s BUY rating with INR 2,400 target. - Expansion targets Brazil, Turkey, LATAM and Southeast Asia.
Why It Matters The rapid scaling of OneSource’s DDC and biologics capabilities signals a strengthening supply chain for semaglutide and other biologics in key emerging markets. As global demand for these therapies rises, the company’s expanded capacity could secure its position as a preferred partner for generic manufacturers, potentially driving revenue growth and shareholder value.
Context Semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist, is widely used for type 2 diabetes and obesity. Generic versions are in high demand as branded products face patent expirations. CDMOs that can produce these drugs at scale are critical to meeting market needs.
What to Watch - The completion of the March 2027 capacity addition. - New market entries in Brazil, Turkey, LATAM and Southeast Asia. - Further client acquisitions in the biologics space. - Any regulatory updates affecting generic semaglutide approvals.
🏛️ Background & Context
Semaglutide is a GLP‑1 receptor agonist used to treat type 2 diabetes and obesity. Generic versions are becoming increasingly important as branded drugs reach the end of their patent life. CDMOs that can manufacture these drugs efficiently are essential to supply chains worldwide.
👁️ What To Watch Next
The firm’s planned March 2027 capacity expansion, entry into new international markets, and additional biologics client agreements are key developments that could influence OneSource’s growth trajectory and stock performance.
